De Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM et al (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69(6):912–920
Medrano RF, Hunger A, Mendonça SA, Barbuto JAM, Strauss BE (2017) Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget 8(41):71249
Article PubMed PubMed Central Google Scholar
Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C et al (2000) Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 156(4):1381–1393
Article CAS PubMed PubMed Central Google Scholar
Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63–68
Article CAS PubMed Google Scholar
Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al (2003) IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69–77
Article CAS PubMed Google Scholar
Wang H, Hu H, Zhang K (2017) Overview of interferon: characteristics, signaling and anti-cancer effect. Arch Biotechnol Biomed 1:1–16
Lee AJ, Ashkar AA (2018) The dual nature of type I and type II interferons. Frontiers in immunology, 2061
Lazear HM, Schoggins JW, Diamond MS (2019) Shared and distinct functions of type I and type III interferons. Immunity 50(4):907–923
Article CAS PubMed PubMed Central Google Scholar
Platanias LC (2005) Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375–386
Article CAS PubMed Google Scholar
Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC (2010) Antiproliferative properties of type I and type II interferon. Pharmaceuticals 3(4):994–1015
Article CAS PubMed PubMed Central Google Scholar
Yoshimura T, Sonoda K-H, Sugahara M, Mochizuki Y, Enaida H, Oshima Y et al (2009) Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE 4(12):e8158
Article PubMed PubMed Central Google Scholar
Banerjee S, Savant V, Scott RA, Curnow SJ, Wallace GR, Murray PI (2007) Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci 48(5):2203–2207
Afarid M, Lashkarizadeh H, Ashraf MJ, Nowroozzadeh MH, Shafiee SM (2016) The efficacy of intravitreal interferon alpha-2b for the treatment of experimental endotoxin-induced uveitis. Indian J Ophthalmol 64(5):376
Article PubMed PubMed Central Google Scholar
Afarid M, Meshksar A, Salehi A, Safarpour MM (2020) Evaluation of the effect of topical interferon α2b as a complementary treatment of macular edema of patients with diabetic retinopathy: a double-blind placebo-controlled randomized clinical trial study. Retina 40(5):936–942
Article CAS PubMed Google Scholar
Afarid M, Azimi A, Malekzadeh M (2019) Evaluation of serum interferons in patients with age-related macular degeneration. J Res Med Sci Official J Isfahan Univ Med Sci 24:24
Kötter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Günaydin I et al (2003) Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87(4):423–431
Article PubMed PubMed Central Google Scholar
Krause L, Turnbull JR, Torun N, Pleyer U, Zouboulis CC, Foerster MH (2004) Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet’s disease. Adamantiades-Behçet’s Disease, 511–9
Sobacı G, Erdem Ü, Durukan AH, Erdurman C, Bayer A, Köksal S et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology 117(7):1430–1435
Park J-Y, Chung Y-R, Lee K, Song JH, Lee E-S (2015) Clinical experience of interferon alfa-2a treatment for refractory uveitis in Behcet’s disease. Yonsei Med J 56(4):1158–1162
Article CAS PubMed PubMed Central Google Scholar
Bielefeld P, Devilliers H, Deschasse C, Saadoun D, Sève P, Muselier A et al (2016) Potential of pegylated interferon alpha-2a in Behçet uveitis: a report of five cases. Ocul Immunol Inflamm 24(5):599–602
Lee JH, Lee CS, Lee SC (2018) Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients. BMC Ophthalmol 18(1):1–4
Eser-Ozturk H, Sullu Y (2019) The results of interferon-alpha treatment in Behçet uveitis. Ocular Immunol Inflamm
Celiker H, Kazokoglu H, Direskeneli H (2019) Long-term efficacy of pegylated interferon alpha-2b in Behçet’s uveitis: a small case series. Ocul Immunol Inflamm 27(1):15–22
Article CAS PubMed Google Scholar
Yalçindag N, Köse HC (2020) Comparison of the treatment results for Behçet uveitis in patients treated with infliximab and interferon. Ocul Immunol Inflamm 28(2):305–314
Atik BK, Altan Ç, Başarir B (2020) Therapeutic outcomes of interferon-alpha-2a treatment in Behçet uveitis Turkiye. Klinikleri J Ophthalmol 29(4):294–299
Qian Y, Qu Y, Gao F, Pei M, Liang A, Xiao J et al (2021) Comparison of the safety and efficacy of interferon alpha-2a and cyclosporine-a when combined with glucocorticoid in the treatment of refractory Behçet’s uveitis: a randomized controlled prospective study. Front Pharmacol 12:699903
Article CAS PubMed PubMed Central Google Scholar
Becker M, Heiligenhaus A, Hudde T, Storch-Hagenlocher B, Wildemann B, Barisani-Asenbauer T et al (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89(10):1254–1257
Article CAS PubMed PubMed Central Google Scholar
Mackensen F, Jakob E, Springer C, Dobner BC, Wiehler U, Weimer P et al (2013) Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am j ophthalmol 156(3):478–486
Article CAS PubMed Google Scholar
Plskova J, Greiner K, Forrester JV (2007) Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am j ophthalmol 144(1):55–61
Article CAS PubMed Google Scholar
Yalcinbayir O, Yucel AA, Kaderli B, Gelisken O (2009) Subconjunctival interferon α-2a application in a case with serpiginous choroidopathy. Retinal Cases Brief Rep 3(2):214–217
Kirkpatrick J, Dick A, Forrester J (1993) Clinical experience with interferon alfa-2a for exudative age-related macular degeneration. British j Ophthal 77(12):766–770
Brasnu E, Wechsler B, Bron A, Charlotte F, Bliefeld P, Lehoang P et al (2005) Efficacy of interferon-α for the treatment of Kaposi’s sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 140(4):746–748
Article CAS PubMed Google Scholar
Invernizzi A, Iannaccone F, Marchi S, Mastrofilippo V, Coassin M, Fontana L, et al (2018) Interferon alpha-2a for the treatment of post-infectious uveitis secondary to presumed intraocular tuberculosis. Ocular Immunol Inflamm
Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis?: A pilot study. Retina 26(7):786–791
Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93(7):906–913
Article CAS PubMed Google Scholar
Maleki A, Aghaei H, Lee S (2018) Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema. Am J Ophthalmol Case Rep 10:203–205
Article PubMed PubMed Central Google Scholar
Deuter CM, Fausel J, Doycheva D, Zierhut M (2019) Long-term results of therapy with interferon alpha in chronic uveitic macular edema. Invest Ophthalmol Visual Sci 60(9):3515
Dimopoulos S, Deuter CM, Blumenstock G, Zierhut M, Dimopoulou A, Voykov B, et al (2019) Interferon alpha for refractory pseudophakic cystoid macular edema (irvine-gass syndrome). Ocular Immunol Inflamm
Aksu-Ceylan N, Cebeci Z, Altinkurt E, Kir N, Oray M, Tugal-Tutkun I (2021) Interferon Alpha-2a for the treatment of cystoid macular edema secondary to acute retinal necrosis. Ocular Immunol Inflamm, 1–10
Maleki A, Stephenson AP, Hajizadeh F (2020) Topical interferon alpha 2b in the treatment of refractory diabetic macular edema. J Ophthalmic Vis Res 15(4):453
PubMed PubMed Central Google Scholar
Faghihi H, Inanloo B, Mirzaee A, Fadakar K, Mirshahi A, Ebrahimiadib N et al (2022) Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema. International Journal of Retina and Vitreous 8(1):1–9
Couret C, Servant M, Lebranchu P, Hamidou M, Weber M (2020) Efficacy and safety of interferon alpha 2a and pegylated interferon alpha 2a in inflammatory macular edema. Ocul Immunol Inflamm 28(2):329–336
Article CAS PubMed Google Scholar
Skowsky WR, Siddiqui T, Hodgetts D, Lambrou FH Jr, Stewart MW, Foster MT Jr (1996) A pilot study of chronic recombinant interferon-alfa 2a for diabetic proliferative retinopathy: metabolic effects and opthalmologic effects. J Diabetes Complications 10(2):94–99
Article CAS PubMed Google Scholar
Fardeau C,
留言 (0)